John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 55,206 shares at $324.12 ($18.0M) on 2025-09-16, disclosed to the SEC on 2025-09-18.
Scheduled sale ($18.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $324.12 | 4,066 | $1.3M | 7.3% |
| 2 | $324.12 | 4,066 | $1.3M | 7.3% |
| 3 | $325.06 | 6,883 | $2.2M | 12.4% |
| 4 | $325.06 | 6,883 | $2.2M | 12.4% |
| 5 | $326.14 | 12,446 | $4.1M | 22.6% |
| 6 | $326.14 | 12,446 |
| $4.1M |
| 22.6% |
| 7 | $326.90 | 4,008 | $1.3M | 7.3% |
| 8 | $326.90 | 4,008 | $1.3M | 7.3% |
| 9 | $327.78 | 400 | $131K | 0.7% |
| Total | $325.70 avg | 55,206 | $18.0M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |